HIMSS16 on the horizon

HIMSS16 is coming up next week and again promises an overwhelming amount of opportunities to learn and network.

I spoke with two of the people behind all the extensive planning needed to pull off such a huge yet timely event, and compiled a list of their suggestions. Read on to learn more about what’s new in the exhibit hall, the keynote addresses and educational sessions.

We also have some recommended sessions of our own. From interoperability to cybersecurity and new payment models to innovation, there’s something for everyone. Hundreds of exhibitors will showcase the latest in solutions addressing everything related to health IT. You can expect to hear from CMS Acting Administrator Andy Slavitt, National Coordinator Karen DeSalvo, MD, MPH, MSc, as well as leaders from providers all over the country who will share their experiences, lessons learned and advice.  

Check back with Clinical Innovation + Technology regularly for updates on all the vendor announcements, government news, partnerships and much more. Best wishes for a successful, insightful and rewarding conference.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.